Prana Biotechnology Limited (PRAN)
-NasdaqCM 2.39 
0.02(0.84%) 1:11PM EDT - Nasdaq Real Time Price
| Prev Close: | 2.37 |
|---|
| Open: | 2.37 |
|---|
| Bid: | 2.36 x 100 |
|---|
| Ask: | 2.39 x 1000 |
|---|
| 1y Target Est: | 6.00 |
|---|
| Beta: | 1.08 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.31 - 2.41 |
|---|
| 52wk Range: | 1.45 - 3.06 |
|---|
| Volume: | 56,299 |
|---|
| Avg Vol (3m): | 162,311 |
|---|
| Market Cap: | 81.42M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.21 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Prana Announces Share Purchase Plan ClosedMarketwired(Fri, May 3)
- Prana Announces $5.8 Million R&D RefundMarketwired(Thu, Apr 4)
- Prana Provides Clinical Trials Safety and Progress UpdateMarketwired(Wed, Apr 3)
- Prana Announces Successful A$7 Million Capital RaisingMarketwired(Wed, Mar 27)
- Prana Details Data Showing That PBT2 Reduces Cognitive Impairment Caused by Tau Protein AccumulationMarketwired(Fri, Mar 8)
- 4 Healthcare Stock Stories Not To Be Overlookedat Wall St. Cheat Sheet(Thu, Mar 7)
- Prana's PBT434 Inhibits Accumulation of Parkinson's Protein and Subsequent Death of Brain Cells.Marketwired(Wed, Mar 6)
- Prana Announces That PBT2 Reduces Cognitive Impairment Caused by Tau Protein AccumulationMarketwired(Mon, Mar 4)
- Prana to Present at Cowen & Company Health Care Conference on March 4th in Boston, MAMarketwired(Mon, Feb 25)
- Prana Announces That New York Academy of Sciences eBriefing Is Available OnlineMarketwired(Tue, Jan 29)
- Prana Biotech Initiated at Mkt Outperform and 3 Initiated Ratings on the Moveat Wall St. Cheat Sheet(Thu, Dec 20)
- Prana Completes Recruitment in Huntington TrialMarketwired(Wed, Dec 19)
- 2 Speculative Biotech Stocks To Consider In The Wake Of Early-Stage Developmentsat Seeking Alpha(Thu, Dec 13)
- Journal of Huntington's Disease Publishes Benefits of PBT2Marketwired(Thu, Dec 13)
- Metal Hypothesis for Alzheimer's, Huntington and Other Neurodegenerative Diseases Declared Promising Therapeutic Strategy by Scientists at New York Academy of Sciences SymposiumMarketwired(Wed, Dec 5)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 19.89 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.48 |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Prana Biotechnology Limited engages in the research and development of therapeutic drugs for the treatment of neurological disorders in Australia. The company primarily focuses on the Alzheimers, Parkinsons, and Huntingtons disea...
View More